http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1660082-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a9cb076caa8b2937d1141c5899b2582 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2004-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b782540e05b7db05d1cd62f7b5a8baf2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_332442a9ea7d2c0ae895c8b22838d2e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfab9896025e5dcecb52d653a2ed5add |
| publicationDate | 2006-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1660082-A1 |
| titleOfInvention | Use of a compound in the treatment of sleep disorders |
| abstract | There is disclosed the use of triprolidine, in combination with at least one further active pharmaceutical agent, for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders is also described. A method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical agent, as active i ingredient to such a person is also described. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing up to 20mg, e.g. 0.1mg, 1.25mg or 2.5mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily. |
| priorityDate | 2003-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 388.